Abstract
ObjectivesThe usefulness of daunorubicin in acute nonlymphocytic leukemia patients is limited by their cardiotoxicity. Current prophylaxis relies upon early detection of systolic and/or diastolic dysfunction. Dexrazoxane reduces cardiac damage during...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
